The aim of this study was to determine the effects of endogenous nitric oxide (NO) on cerebral blood flow (CBF) and cerebrovascular resistance (CVR) under conditions of normoxia and hypoxia. Experiments were performed on anesthetized, mechanically ventilated Wistar rats. CBF was measured using the intracarotid 133Xe injection technique. NO formation was inhibited by W-monomethyl-L-arginine (L -NMMA). Administration of L-NMMA (100 mg kg-I i.v.) during normoxia resulted in an increase in mean arterial blood pressure from 113 ± 4 to 145 ± 4 mm Hg (p < 0.001), a decrease in CBF of 21% (from 91 ± 4 to 75 ± 5 ml 100 g-I min-I, p < 0.001), and an increase in CVR of 53% (from 1.3 ± 0.1 to 2.0 ± 0.2 mm Hg ml-1 100 g min, p < 0.001). These effects were reversed by i.v. administration of 300 mg kg-1 of Recently published data (Grote et aI ., 1988; Pearce, 1989) suggest that hypoxia can relax iso lated cerebral arteries directly through hyperpolar-
It is well known that hypoxemia leads to cerebral vasodilation and an increase in cerebral blood flow (CBF) in different species (Kety and Schmidt, 1948; Cohen et aI ., 1967; Borgstrom et aI ., 1975; Trayst man et aI., 1978; Wagerle et aI ., 1983) . The exact mechanism of this phenomenon is not known, al though the list of candidates that might be involved comprises a great number of vasoactive metabolites (Borgstrom et aI ., 1975; Folbergova et aI ., 1981; Winn et aI., 1981; Koehler and Traystman, 1982 ; Morii et aI. , 1987) . L-arginine but not o-arginine. Moreover, the administra tion of L-NMMA abolished the enhancement of CBF and the diminution in CVR observed during intracarotid infu sion of acetylcholine (ACh). The increase in CBF and decrease in CVR during hypoxia in the group of rats that received L-NMMA were similar to that in the control group, although CBF and CVR levels attained during hypoxia in both groups were different. The results show that NO is involved in the maintenance of basal CBF and CVR, and is responsible for the ACh-elicited increase in CBF and the decrease in CVR in rats. They also suggest that NO modulates hypoxic changes of CBF and CVR, but is probably not the main factor responsible for the increase in CBF during hypoxia. Key Words: Cerebral blood flow-NO-L-NMMA-Normoxia-Hypoxia.
ization of vascular smooth muscle and/or through the release of endothelium-derived relaxing factor (EDRF), which was identified as endothelium derived nitric oxide (NO) (Moncada et aI ., 1988b; KeIrn et aI ., 1989; Rees et aI ., 1989a) . The main action of NO/EDRF is the stimulation of the soluble guanylate cyclase, which causes an increase in cGMP in vascular smooth muscle (Moncada et aI ., 1988a) , leading to relaxation .
The release of EDRF and an increase in cGMP in vascular smooth muscle cells during hypoxia was observed in isolated segments of basilar, internal, and common carotid arteries by Pearce (1989) and Pearce et aI . (1989) . These effects were blocked by removal of endothelium or by prior treatment with methylene blue, which is known to decrease cGMP accumulation following EDRF release (Martin et aI., 1985a) .
Thus far, the effects of NO on cerebral blood flow have not been investigated . The aim of our study was to find out whether NO participates in the maintenance of basal, normoxic CBF and cerebral vascular resistance (CVR) and whether an increase in CBP observed during hypoxia depends upon the release of endothelium-dependent NO .
MATERIAL AND METHODS
The experiments were performed on 22 male Wistar rats weighing 225-290 g. The animals had free access to water and commercial chow pellets. During the experi ment, they were anesthetized with chloral hydrate (36 mg 100 g-I of body weight), paralyzed with pancuronium (0.05 mg 100 g -I of body weight), and artificially venti lated with air in which the impaired oxygen fraction (FiOz) was 0.3. Body temperature was controlled and maintained around 37°C with a heating pad. A femoral artery and vein were cannulated to allow measurements of mean arterial blood pressure (MABP), arterial blood sampling for gasometric analysis (PaOz, PaCOz, and pH), drug administrations, and supplementation of anesthesia.
CBF was determined by the intracarotid 133Xe injection technique according to the method introduced by Hertz et al. (1977) . The catheter for xenon injection was placed centripetally in the external carotid artery after ligation of the pterygopalatine artery and the small branches of the external carotid artery on the side of isotope injection. For CBF measurement, a bolus of 133Xe was injected in a volume of 15-50 IJ.J of physiological saline solution.
The radioactivity of xenon was detected by a well collimated scintillation crystal attached to a photomulti plier mounted over the ipsilateral temporoparietal region. CBF was calculated from the initial slope (15 s) of the semilogarithmically displayed clearance curve and ex pressed in ml 100 g -1 min -I .
To obtain cerebral venous blood from the sagittal sinus, the cranium was punctured 3 mm anterior to the lambda suture using a I-mm hypodermic needle.
At each CBF determination, both arterial and cerebral venous oxygen content were measured (hemoximeter OSM2, Radiometer) and the cerebral metabolic rate for oxygen (CMROz) was calculated from the arteriovenous oxygen difference using the Fick principle and expressed in ml 100 g -1 min -I. Blood gas analysis was performed at each CBF measurement (A VL gas check 995-Hb, A VL).
Cerebral vascular resistance (CVR) was calculated as the ratio of MABP to CBF and expressed in mm Hg ml-1 100 g min.
Four groups of experiments were performed. In the first group (n = 9), after control normoxic measurement of CBF and CMROz, 100 mg kg-' of W-monomethyl-L arginine (L -NMMA) was injected intravenously in a vol ume of 0.3 ml of physiological saline solution over 60 s. This drug was used to block the formation of NO from its precursor, L-arginine (Palmer et aI., 1988) . CBF and CMROz were measured at 5, 15, and 30 min following drug injection. Immediately after the last CBF measure ment, ventilation was switched to hypoxia (FiOz = 0.12). CBF and CMROz were measured 5 min later.
In the second group of animals (n = 9), hypoxia (FiOz = 0.12) was induced after completion of control, nor moxie CBF and CMROz measurements. CBF and CMROz measurements were repeated at 5 min following the onset of hypoxic ventilation. This group served as the control for hypoxemia.
In the third group of animals (n = 5), 15 min following L-NMMA (100 mg kg -1 Lv.) administration, D-arginine J Cereb Blood Flow Metab, Vol. 12, No.2, 1992 (300 mg kg -I) and 15 min later L-arginine (300 mg kg -I) were injected Lv. over 30 s. Each drug was administered in 0.3 ml of physiological saline solution. CBF, CVR, and CMROz were measured before L-NMMA, 10 min follow ing L-NMMA administration, and 10 min after D-and 10 min after L-arginine injection. MABP was recorded con tinuously.
In the fourth group of rats (n = 4), ligation of the ptery gopalatine artery and the retrograde cannulation of the external carotid artery were performed bilaterally in or der to enable the infusion of acetylcholine chloride (ACh, Sigma) into the cerebral circulation and the simultaneous measurement of CBF. In this group of animals, CBF and CVR were measured before and 5 min after the onset of intracarotid infusion of ACh. The ACh was delivered through a microprocessor syringe pump (Harvard Appa ratus) at a rate of 10 fLg min -I . Fifteen minutes after the cessation of ACh infusion, CBF and CVR were measured again. Upon completion of this measurement, the L-NMMA dose (100 mg kg-' i.v.) was administered. Fol lowing this, the effect of ACh on CBF and CVR was tested once more in the same pattern as above.
The effect of intravenous administration of 0.3 ml of 0.9% NaCI (vehicle) on the measured parameters was studied in a separate group of four rats. It had no effect and therefore was not administered to the rest of animals.
In a pilot group of experiments, the effects of 100 mg kg-' of L-NMMA on MABP, CBF, CMROz, and CVR was studied up to 60 min after administration in order to be sure that the drug still acts during hypoxic exposure.
All data were presented as means :t SD. Statistical differences were evaluated with analysis of variance (ANOV A) for repeated or independent measurements ap plied to appropriate data. Individual comparisons be tween groups were performed using the Newman-Keuls test. p values <0.05 were considered statistically signifi cant.
RESULTS
L-NMMA caused a decrease in CBP and an in crease in CVR . CBP measured at 5 min following administration of 100 mg kg -I i. v. of L-NMMA de creased by 21% (p < 0.001) of control and remained at about the same level during the observation time of 30 min (Pig . 1, Table 1 ). CVR was augmented by 53% (p < 0.001) of control 5 min after L-NMMA injection . This increase was also maintained throughout the experiment (Pig . 1, Table 1 ).
L-NMMA administration did not affect CMR02• The drug also caused an increase in MABP (Pig. Table 1 ). This effect was rapid, reaching a plateau within 3 min, and was maintained during the obser vation time .
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The effects of L-NMMA on the measured vari ables were reversed following the administration of L-arginine (300 mg kg-1 i.v.). D-arginine adminis tered at the same dose was without effect ( Table 2) , which supports the stereospecificity and competi tive action of L-NMMA.
Results of the next group of experiments (Table   3 ) demonstrate an increase in CBP (by 68% of con-
Cerebral blood flow (CBF), cerebral metabolic rate for oxygen (CMR02), and cerebral vascular resistance (CVR) before (con) and after the administration (arrow) of L-NMMA (100 mg kg-1 Lv.). trol value, p < 0.0 1) and a decrease in CVR (to 67% of control value, p < 0.02) during intracarotid infu sion of ACh (10 fLg min -I) . Changes of CBF and CVR during ACh infusion at the same rate were absent following administration of 100 mg kg-I of L-NMMA, which shows that the dose of the drug was sufficient to abolish the endothelium dependent increase in CBF during normoxia.
Hypoxemia (Pa02 = 33 ± 3 mm Hg) resulted in an increase in CBF of 135% (p < 0.001) and a de crease in CVR of 64% (p < 0.001) of the control norm oxic value in the group of rats that did not receive L-NMMA ( Fig. 3 , Table 4 ). CMR02 re mained at the control level. Lowering of Pa02 in this group also caused a decrease in MABP of 19% (p < 0.01).
The effects of hypoxemia (Pa02 = 33 ± 6 mm Hg) on CBF and CVR in the group of rats which received L-NMMA are presented in Fig. 3 . In this group, CBF increased during hypoxemia by 95% of the control normoxic value (p < 0.001) during hyp oxemia and this rise was not significantly different from that observed in the control group. The CVR decrease during hypoxemia in this group of 53% (p < 0.001) of the control normoxic value measured following L-NMMA administration was not differ ent from the decrement observed in the control group.
However, in absolute terms, the maximum CBF during hypoxemia was significantly smaller (p < 0. 0 1) and the minimum CVR was significantly greater (p < 0.05) after L-NMMA than in the control group.
CMR02 during hypoxemia did not change, as in the control hypoxemic group.
The MABP during hypoxemia following L-NMMA administration had a tendency to de crease but this decrease was not statistically signif icant.
DISCUSSION
The main finding of the present study is a de crease in CBF and an increase in CVR following the administration of L-NMMA. Since L-NMMA is a specific inhibitor of endothelium-derived NO for mation (Palmer et aI., 1988) and the dose of L-NMMA in our study was sufficient to block the endothelium-dependent increase in CBF, this study suggests that endogenous NO is involved in the maintenance of basal CBF and CVR in the rat, all TABLE 1. Effects of L-NMMA on cerebral and systemic variables CBF (ml 100 g-l min-I ) CMR02 (ml 100 g-l min-I ) CVR (mm Hg ml-l 100 g min) MABP (mm Hg) Pa02 (mm Hg) PaC02 (mm Hg) pH Data are means ± SD, n = 9. *** p < 0.001 (L-NMMA vs. control).
Control 94 ± 12 8.5 ± 0.9 1.3 ± 0.3 112 ± 12 110 ± 15 33 ± 3 7.47 ± 0.03 " Following 100 mg kg-l i.v. of L-NMMA.
min"
75 ± 15*** 8.3 ± 1.5 2.1 ± 0.6*** 145 ± 12*** 106 ± 18 33 ± 3 7.46 ± 0.03 15 min" 71 ± 12*** 8.2 ± 1.2 1.9 ± 0.3*** 132 ± 18*** 101 ± 18 33 ± 3 7.45 ± 0.03 30 min" 73 ± 15*** 7.9 ± 2.1 1.9 ± 0.6*** 133 ± 24*** 100 ± 21 33 ± 3 7.42 ± 0.03 c.. It was also reported that in isolated rabbit hearts L-NMMA caused dose-related increases in coro nary perfusion pressure that were attenuated by L-arginine (Amezcua et aI., 1989) .
Our results also confirm the observation made by Control 64 ± 7 122 ± 7 1.9 ± 0.2 10 min after L-NMMA 47 ± 4*** 141 ± 9*** 3.0 ± 0.2*** 10 min after o-arginine 48 ± 2*** 142 ± 11*** 3.0 ± 0.2*** 10 min after L-arginine 65 ± 7 122 ± 7 1.9 ± 0.2
Data are means ± SO, n = 5. *** p < 0.001 vs. control.
the difference of BP and ICP to CBF. We did not measure ICP in the present experiments but we know from previous studies that it is close to zero and not affected in a measurable way by the in crease in CBF during the CO2 test (unpublished data).
Thus, we assume that the cerebral perfusion pres sure is close to the MABP value and that the in crease in CBF did not produce an increase in ICP.
Even if this is not the case, the increase in ICP would result in a drop in perfusion pressure and this would give a greater than calculated drop in CVR.
The next problem is connected with the increase in MABP and CVR observed following inhibition of NO synthesis. One could argue that the increase in The present data suggest that NO is responsible for vasodilation following ACh in the cerebrovas cular bed since administration of L-NMMA abol ished the increase in CBF and the decrease in CVR in response to ACh infusion. Data are means ± SD, n = 4. ** p < 0.02, ***p < 0.01 (ACh vs. control). t p < 0.05, ttp < 0.02 (control following L-NMMA vs. control). a Following L-NMMA.
The role of endothelium and EDRF in the relax ation to ACh of large cerebral arteries in vitro and pial arterioles in vivo has already been established (Lee, 1982; Lee et aI., 1982; Fujiwara et aI., 1986; Rosenblum, 1986) . 
1989
; Rees et aI., 1989a; Whittle et al., 1989; Gar diner et aI., 1990; Tolins et aI., 1990; Chu et aI., 1991) including humans (Vallance et aI., 1989) .
Our study suggests that NO modulates the hyp oxic response in the cerebral circulation. Some pre vious studies suggested participation of endothe lium in the hypoxic dilation of isolated cerebral ar teries (Pearce, 1989; Pearce et aI., 1989) . Scraping of the endothelium or application of methylene blue, which is known to block the effects of EDRF (Martin et aI., 1985a) , prevented dilation of these vessels during hypoxia.
The role of endothelium in hypoxic vasodilation was postulated by Busse et ai. (1983) . ygen was transported to the brain during hypoxia after pretreatment with L-NMMA, provided that the inhibition of NO formation did not increase the oxygen-carrying capacity of the blood.
If we assume that there is a decrease in oxygen transport to the brain, then the data indicate that other factors regulating CBF during hypoxia, i.e., locally released metabolites, are insufficient to in sure adequate blood supply to the brain during in hibition of NO production. This would mean that endothelial NO production during hypoxemia is es sential for the increase in cerebral blood flow under this condition.
The assumption that inhibition of NO synthesis during hypoxia changes the oxygen-carrying capac ity of hemoglobin or shifts its oxygen dissociation curve is a speculative one. It is known that hemo globin inactivates EDRF by binding it to the heme moiety (Martin et aI., 1985b) and that the affinity of NO to hemoglobin is much greater than that of ox ygen (Gibson and Roughton, 1957) . Thus, one may speculate that the increased production of NO dur ing hypoxia results in a decrease in the oxygen transporting capabilities of the blood by blocking hemoglobin. Administration of an inhibitor of NO synthase (L-NMMA) caused an increase in the amount of hemoglobin available for the binding of oxygen.
Thus, in such a case, more oxygen would be de livered to the brain at a given level of hypoxemia. In order to verify this hypothesis, one has to measure the local partial pressure of oxygen in the brain un der these conditions. On the basis of our results, we Hypoxia Normoxiaa Hypoxiaa 200 ± 51*** 73 ± 15 143 ± 63*** 6.9 ± 1.2 7.9 ± 2.1 7.4 ± 1.8 0.5 ± 0.3*** 1.9 ± 0.6 0.9 ± 0.3*** 98 ± 18** 133 ± 24 115 ± 30 33 ± 3*** 100 ± 21 33 ± 6*** 30 ± 3 33 ± 3 26 ± 6** 7.36 ± 0.09 7.42 ± 0.03 7.39 ± 0.09
can only say that endogenous NO modulates the CBF response to hypoxia.
The release of L-arginine and thus generation of NO during hypoxia may increase to such an extent that the dose of L-NMMA that was sufficient during normoxic conditions was too small to block the re lease of NO during hypoxia. The argument against it is the behavior of MABP during hypoxia. If the dose of L-NMMA was too small to block NO pro duction during hypoxia, then one should expect a decrease in MABP due to NO-elicited relaxation of resistance vessels, which was not the case. On the contrary, in the group of rats pretreated with L-NMMA, the MABP during hypoxemia did not de crease and was higher than in the control hypox emic group.
Thus, we conclude that endothelium-derived ni tric oxide participates in the regulation of CBF and CVR under normoxic condition, is responsible for the increase in CBF and the decrease in CVR ob served following ACh infusion, and modulates the response of CBF and CVR during hypoxia.
